Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  190 results for ""Antineoplastic Agents, Immunological""

Your Filters

Publisher : nature publishing group
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer.

  • Authors : Jiang CY; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: Scientific reports [Sci Rep] 2024 Jan 03; Vol. 14 (1), pp. 345. Date of Electronic Publication: 2024 Jan 03.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

Record details

Read More Add to Saved list
×
Editorial & Opinion

Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients-role of maintenance therapy in the real world.

  • Authors : Damlaj M; Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia. .; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. .

Subjects: Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/drug therapy ; Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/pathology ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/therapeutic use

  • Source: Bone marrow transplantation [Bone Marrow Transplant] 2023 Oct; Vol. 58 (10), pp. 1160-1162. Date of Electronic Publication: 2023 Jul 18.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment.

  • Authors : Yang J; Department of Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.; Bae H

Subjects: Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Neoplasms*/Neoplasms*/Neoplasms*/pathology ; Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/pharmacology

  • Source: Experimental & molecular medicine [Exp Mol Med] 2023 Sep; Vol. 55 (9), pp. 1996-2004. Date of Electronic Publication: 2023 Sep 01.Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9607880 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab.

  • Authors : Hosoya T; Division of Neurosurgery, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, 36-1, Nishi-cho, Yonago, 683-8504, Tottori, Japan.; Kambe A

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/therapeutic use ; Bevacizumab*/Bevacizumab*/Bevacizumab*/adverse effects ; Glioma*/Glioma*/Glioma*/drug therapy

  • Source: Scientific reports [Sci Rep] 2024 Nov 02; Vol. 14 (1), pp. 26419. Date of Electronic Publication: 2024 Nov 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/pharmacology ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use

  • Source: Scientific reports [Sci Rep] 2024 Oct 04; Vol. 14 (1), pp. 23136. Date of Electronic Publication: 2024 Oct 04.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.

  • Authors : Wang C; Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.; Bai C

Subjects: Trastuzumab*/Trastuzumab*/Trastuzumab*/pharmacology ; Trastuzumab*/Trastuzumab*/Trastuzumab*/therapeutic use ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy

  • Source: Cancer gene therapy [Cancer Gene Ther] 2024 Oct; Vol. 31 (10), pp. 1525-1535. Date of Electronic Publication: 2024 Aug 10.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab.

  • Authors : Khattri A; Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. .; Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, India. .

Subjects: Cetuximab*/Cetuximab*/Cetuximab*/pharmacology ; Cetuximab*/Cetuximab*/Cetuximab*/therapeutic use ; ErbB Receptors*/ErbB Receptors*/ErbB Receptors*/genetics

  • Source: Cancer gene therapy [Cancer Gene Ther] 2024 Oct; Vol. 31 (10), pp. 1477-1485. Date of Electronic Publication: 2024 Jul 31.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab.

  • Authors : Kasahara Y; Department of Medical Oncology, Tohoku University Hospital, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.; Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Neutrophils* ; Lymphocytes*

  • Source: Scientific reports [Sci Rep] 2024 Nov 16; Vol. 14 (1), pp. 28255. Date of Electronic Publication: 2024 Nov 16.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro.

Subjects: Complement C1q*/Complement C1q*/Complement C1q*/metabolism ; Complement C1q*/Complement C1q*/Complement C1q*/immunology ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/pharmacology

  • Source: Scientific reports [Sci Rep] 2024 Nov 15; Vol. 14 (1), pp. 28239. Date of Electronic Publication: 2024 Nov 15.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.

  • Authors : Abdel-Wahed MA; Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, 38 Abbassyia Square, Cairo, Egypt. .; Sabbour GS

Subjects: Trastuzumab*/Trastuzumab*/Trastuzumab*/therapeutic use ; Receptors, IgG*/Receptors, IgG*/Receptors, IgG*/genetics ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/genetics

  • Source: Scientific reports [Sci Rep] 2024 Oct 29; Vol. 14 (1), pp. 26037. Date of Electronic Publication: 2024 Oct 29.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

Record details

Read More Add to Saved list
×
  • 1-10 of  190 results for ""Antineoplastic Agents, Immunological""